Meeting the UK demand for COVID19/SARS-CoV-2 vaccines via integrated manufacturing and supply chain optimisation

We shall deliver a blueprint for simultaneously ramping up production and ensuring uninterrupted delivery of SARS-CoV-2 vaccines in the UK to manage and prevent subsequent waves of the pandemic. We shall assist decision-making of manufacturers, governments and stakeholders during SARS-CoV-2 vaccine manufacture and distribution to ensure increased vaccine availability particularly during early stages of manufacturing. The proposed work will consider the UK population in its entirety from the outset with respect to both the population stratification strategy, based on health, disease exposure and socio-environmental risks, and vaccine distribution networks throughout the country including remote communities. Through our involvement in the vaccine hubs funded by the Department of Health (EP/R013764/1 and EP/R013756/1), we have developed world-leading capabilities in vaccine manufacturing and supply chain modelling and optimisation. Early access to the vaccine development efforts by the Jenner Institute in Oxford and the Shattock group at Imperial, has enabled us to develop accurate manufacturing models that will underpin the proposed research. We have access to a remarkable network of key UK and international vaccine stakeholders (CEPI, IAVI), manufacturers (GSK), BIA (via CPI) and governmental bodies, such as the Department of Health who will provide feedback and datasets.